Feature Channels: Immunology

Filters close
Newswise: ‘Dynamic duo’ defenses in bacteria ward off viral threats
Released: 22-Feb-2024 8:05 PM EST
‘Dynamic duo’ defenses in bacteria ward off viral threats
University of Southampton

Scientists at the University of Southampton have discovered that bacteria can pair up their defense systems to create a formidable force, greater than the sum of its parts, to fight off attack from phage viruses.

Newswise: Study Reveals New Insights Into Immune System Role in Lung Cancer Risk
19-Feb-2024 10:05 AM EST
Study Reveals New Insights Into Immune System Role in Lung Cancer Risk
Mount Sinai Health System

Recent developments in cancer research have highlighted the vital role of the immune system, particularly in the notable successes of cancer immunotherapy. Now, a paradigm-shifting study led by researchers at the Icahn School of Medicine at Mount Sinai in New York in collaboration with the University of Helsinki and Massachusetts General Hospital sheds light on how variations in immune genetics influence lung cancer risk, potentially paving the way for enhanced prevention strategies and screening. The findings were described in the February 22 online issue of Science.

Released: 22-Feb-2024 11:05 AM EST
Immune Cell Receptor Provides Promising Immunotherapy Target
Johns Hopkins Medicine

Drugs that target a receptor on immune cells called activin receptor 1C may combat tumor-induced immune suppression and help patients’ immune systems fight back against cancer, according to a study by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

Released: 21-Feb-2024 2:05 PM EST
Long COVID can happen to anyone. Keep up with the latest research on Long COVID on Newswise
Newswise

Stay informed! These are the latest research articles on "Long COVID" from the Coronavirus News Source on Newswise.

19-Feb-2024 9:05 AM EST
Long COVID linked to persistently high levels of inflammatory protein: a potential biomarker and target for treatments
University of Cambridge

SARS-CoV-2 triggers the production of the antiviral protein IFN-γ, which is associated with fatigue, muscle ache and depression. New research shows that in Long COVID patients, IFN-y production persists until symptoms improve, highlighting a potential biomarker and a target for therapies.

access_time Embargo lifts in 2 days
This news release is embargoed until 25-Feb-2024 1:45 PM EST Released to reporters: 21-Feb-2024 12:00 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 25-Feb-2024 1:45 PM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise:Video Embedded diesel-exhaust-may-harm-immune-system-trigger-inflammation
VIDEO
Released: 21-Feb-2024 7:55 AM EST
Diesel Exhaust May Harm Immune System, Trigger Inflammation
American Physiological Society (APS)

Exposure to diesel exhaust particles triggers higher levels of inflammation, especially during a respiratory infection.

   
Released: 21-Feb-2024 1:05 AM EST
The immune system’s moonlighters
Cold Spring Harbor Laboratory

Our immune system is remarkably powerful. It quickly assembles teams of cells to eliminate threats inside our bodies.

Released: 20-Feb-2024 4:05 PM EST
New cell-based immunotherapy offered for melanoma
Washington University in St. Louis

Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, is one of the first centers nationwide to offer a newly approved cell-based immunotherapy that targets melanoma.

Released: 20-Feb-2024 9:00 AM EST
Leading experts share latest science on global health threats from endocrine disrupting chemicals
Endocrine Society

As delegates from around the world meet at the sixth session of the U.N. Environmental Assembly (UNEA-6), a new report raises concerns about the profound threats to human health from endocrine-disrupting chemicals (EDCs) that are ubiquitous in our surroundings and everyday lives.

Released: 20-Feb-2024 8:00 AM EST
Sylvester Comprehensive Cancer Center Tip Sheet for Feb. 2024
Sylvester Comprehensive Cancer Center

A guitarist begins 2024 on high note after awake brain surgery, Dr. Damian Green named chief of Transplantation & Cellular Therapy, targeting treatment resistance in CLL, expanding the patient pool for immunotherapy, researching potential new treatments for head and neck cancer, and more are included in this month’s tip sheet.

Released: 19-Feb-2024 10:05 PM EST
Widely used machine learning models reproduce dataset bias in Rice study
Rice University

High-income communities overrepresented in relevant datasets for immunotherapy research.

   
Newswise: Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas
Released: 16-Feb-2024 10:05 AM EST
Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas
University of California, Los Angeles (UCLA), Health Sciences

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.

Released: 15-Feb-2024 3:05 PM EST
Alerta do especialista: saúde e células zumbi durante o envelhecimento
Mayo Clinic

Com o avanço da idade, as células podem sofrer envelhecimento, um estado no qual elas param de crescer, mas continuam liberando moléculas inflamatórias e tecido degradado.

Released: 15-Feb-2024 3:05 PM EST
تحذير خبراء: خلايا الصحة والخلايا الزُومبيّ في الشيخوخة
Mayo Clinic

مدينة روتشستر، ولاية مينيسوتا —مع تقدم السن، يمكن أن تتعرض الخلايا للشَيخُوخَة، وهي حالة تتوقف فيها عن النمو ولكنها تستمر في إطلاق جزيئات التهابية وجزيئات مدمرة للأنسجة. عندما يكون الشخص صغيرًا في السن، يستجيب الجهاز المناعي ويطرح الخلايا الهَرِمة، والتي يشار إليها غالبًا باسم الخلايا الزُومبيّ. ومع ذلك، تبقى خلايا الزُومبيّ باقية وتساهم في العديد من المشاكل والأمراض الصحية المرتبطة بالعمر. سلط الباحثون في مايو كلينك، في دراستين، الضوء على بَيولُوجْيا خلايا الشَيخُوخَة.

Newswise: inhalable-extracellular-vesicle-delivery-of-il-12-mrna-to-treat-lung-cancer-promote-systemic-immunity_0.png
Released: 15-Feb-2024 12:05 AM EST
Study Finds New Inhalable Therapy is a Big Step Forward in Lung Cancer Research
Columbia University School of Engineering and Applied Science

Columbia Biomedical Engineer Ke Cheng has developed a technique that uses inhalation of exosomes, or nanobubbles, to directly deliver IL-12 mRNA to the lungs of mice.

Newswise: Researchers Characterize the Immune Landscape in Cancer
12-Feb-2024 11:05 AM EST
Researchers Characterize the Immune Landscape in Cancer
Mount Sinai Health System

Researchers from the Icahn School of Medicine at Mount Sinai, in collaboration with the Clinical Proteomic Tumor Analysis Consortium of the National Institutes of Health, The University of Texas MD Anderson Cancer Center, Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, and others, have unveiled a detailed understanding of immune responses in cancer, marking a significant development in the field. The findings were published in the February 14 online issue of Cell. Utilizing data from more than 1,000 tumors across 10 different cancers, the study is the first to integrate DNA, RNA, and proteomics (the study of proteins), revealing the complex interplay of immune cells in tumors. The data came from the Clinical Proteomic Tumor Analysis Consortium (CPTAC), a program under the National Cancer Institute.

Newswise: Researchers Uncover Mechanisms behind Enigmatic Shapes of Nuclei
13-Feb-2024 11:00 AM EST
Researchers Uncover Mechanisms behind Enigmatic Shapes of Nuclei
University of California San Diego

White blood cells known as neutrophils feature a nucleus that is structured strikingly different than most nuclei. These unique shapes permit neutrophils to travel all over the body to combat invading pathogens.

   
Released: 13-Feb-2024 10:05 PM EST
Interactions between flu subtypes predict epidemic severity more than virus evolution
eLife

Researchers have shed new light on how viral evolution, population immunity, and the co-circulation of other flu viruses shape seasonal flu epidemics.

Released: 13-Feb-2024 11:05 AM EST
Life doesn't stop at age 65. Get the latest on seniors and healthy aging in the Seniors channel
Newswise

Below are some of the latest research and features on this growing population of older adults in the Seniors channel on Newswise.

Newswise: New Trial Highlights Incremental Progress Towards a Cure for HIV-1
Released: 13-Feb-2024 9:00 AM EST
New Trial Highlights Incremental Progress Towards a Cure for HIV-1
University of North Carolina School of Medicine

A new clinical trial, led by clinicians and researchers at the UNC School of Medicine, show that the combination of the drug vorinostat and immunotherapy may modestly shrink the latent HIV reservoir, but more work needs to be done in the field to create a cure.

12-Feb-2024 5:05 PM EST
Immunotherapy before surgery leads to promising long-term survival in sarcoma patients
University of Texas MD Anderson Cancer Center

Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to Phase II trial results published today in Nature Cancer by researchers at The University of Texas MD Anderson Cancer Center

Newswise: Novel bispecific design improves CAR T–cell immunotherapy for childhood leukemia
Released: 12-Feb-2024 11:55 AM EST
Novel bispecific design improves CAR T–cell immunotherapy for childhood leukemia
St. Jude Children's Research Hospital

Findings from St. Jude Children’s Research Hospital showed a novel dual targeting approach, where a single molecule can recognize two potential cancer-related proteins, is more effective than the single targeting approach, preventing immune escape.

Released: 12-Feb-2024 10:05 AM EST
Encefalite: Especialista da Mayo Clinic explica por que o tratamento precoce é importante
Mayo Clinic

A Encefalite é uma doença que envolve a inflamação ou inchaço do cérebro. Isso pode acontecer devido a infecções ou problemas no sistema imunológico, e o tratamento precoce é importante.

Released: 12-Feb-2024 10:05 AM EST
التهاب الدماغ: يشرح خبير من مايو كلينك سبب أهمية العلاج المبكر
Mayo Clinic

التهاب الدماغ هو مرض ينطوي على التهاب أو تورم الدماغ. ويمكن أن يحدث بسبب التهابات أو مشكلات تصيب الجهاز المناعي، والعلاج المبكر لتلك الحالة مهم. يقول ساروش إيراني، بكالوريوس الطب والجراحة.، طبيب الأعصاب، وباحث في مايو كلينك في جاكسونفيل، فلوريدا أنه لهذا السبب من الضروري رفع مستوى الوعي.

Released: 12-Feb-2024 10:05 AM EST
Encefalitis: Experto de Mayo Clinic explica por qué es importante el tratamiento temprano
Mayo Clinic

La Encefalitis es una enfermedad que implica inflamación o hinchazón del cerebro. Esto puede suceder debido a infecciones o problemas con el sistema inmunológico, y el tratamiento temprano es importante.

Released: 8-Feb-2024 8:50 AM EST
Atlantic Health System Enrolls First U.S. Patient in Lupus Treatment Trial
Atlantic Health System

NJ-based Atlantic Health System is the first in the U.S. to enroll a patient in a study to examine the effectiveness of using Chimeric Antigen Receptor (CAR- T) cells in the treatment of the autoimmune disease lupus.

Released: 7-Feb-2024 12:00 PM EST
Renowned Immunologist Dr. Gary Koretzky to Receive AAI Lifetime Achievement Award Honoring Exceptional Contributions to Immunology
American Association of Immunologists (AAI)

Recognizing the impact of his research and outstanding leadership in the field of immunology, Gary Koretzky, M.D., Ph.D., DFAAI (AAI ’92), will receive the American Association of Immunologists (AAI) Lifetime Achievement Award, the association’s highest honor, at the AAI annual conference IMMUNOLOGY2024TM, May 3-7 in Chicago.

   
Newswise: How T cells combat tuberculosis
Released: 6-Feb-2024 11:05 AM EST
How T cells combat tuberculosis
La Jolla Institute for Immunology

Scientists at La Jolla Institute for Immunology (LJI) have uncovered important clues to how human T cells combat the bacterium that causes tuberculosis.

Newswise: Immune networks in tumors prime responses to a personalized immunotherapy
Released: 6-Feb-2024 11:05 AM EST
Immune networks in tumors prime responses to a personalized immunotherapy
Ludwig Cancer Research

Through an analysis of tumor samples collected over time from patients with advanced melanoma, a Ludwig Cancer Research study has identified a set of preexisting conditions in tumors that predict whether such patients are likely to respond to a personalized immunotherapy known as adoptive T cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL).

1-Feb-2024 11:05 AM EST
Immune response, not acute viral infections, responsible for neurological damage, McMaster researchers discover
McMaster University

For years, there has been a long-held belief that acute viral infections like Zika or COVID-19 are directly responsible for neurological damage, but researchers from McMaster University have now discovered that it’s the immune system’s response that is behind it.

Released: 1-Feb-2024 10:05 PM EST
Gut bacteria can process dietary fiber into an anti-allergy weapon, finds new study
Tokyo University of Science

The intricate relationship that exists between humans and the gut microbiome has become a hot research topic, and scientists are constantly uncovering new reasons why a healthy diet can lead to a healthier life.

Newswise:Video Embedded live-event-nurses-the-most-trusted-profession-in-an-age-of-mistrust
VIDEO
Released: 1-Feb-2024 5:00 PM EST
VIDEO AND TRANSCRIPT: Nurses -- The Most Trusted Profession in an Age of Mistrust
Newswise

For 21 years, nurses have consistently been the most trusted profession, according to the yearly Gallup poll. (The new poll will be issued by the end of January). Dr Rushton, who specializes in burnout, will speak on trust, moral injury, and how nurses cope in this day and age.

Newswise:Video Embedded why-a-targeted-therapy-is-better-than-immunotherapy-for-some-patients-with-inoperable-non-small-cell-lung-cancer
VIDEO
Released: 31-Jan-2024 7:05 PM EST
Why a Targeted Therapy Is Better Than Immunotherapy For Some Patients With Inoperable Non-Small Cell Lung Cancer
Yale Cancer Center/Smilow Cancer Hospital

Non-small cell lung cancer (NSCLC), with an epidermal growth factor receptor (EGFR) mutation, tends not to respond well to immunotherapy treatments, including durvalumab. However, Yale Cancer Center (YCC) researchers recently reported in the Journal of Thoracic Oncology that the targeted therapy osimertinib, when administered after chemotherapy and radiation, is associated with significantly improved progression-free survival (living without the cancer worsening).

Released: 31-Jan-2024 5:05 PM EST
Molecule can quickly, and briefly, boost white blood cell counts
Yale University

Treatment with a molecule known as A485 can quickly and temporarily increase levels of white blood cells, a critical part of the body’s immune system, an effect that is difficult to deliver with currently available pharmaceuticals, a new Yale study finds.

Newswise: Brain Protein's Virus-Like Structure May Help Explain Cancer-Induced Memory Loss
24-Jan-2024 11:00 AM EST
Brain Protein's Virus-Like Structure May Help Explain Cancer-Induced Memory Loss
University of Utah Health

In a rare but serious complication of cancer, the immune system can start attacking the brain, causing rapid memory loss. What triggers this was largely unknown. Now, researchers at University of Utah Health have found that some tumors can release a virus-like protein, kickstarting an out-of-control autoimmune reaction.

Released: 30-Jan-2024 2:05 PM EST
Our winter of discontent: Get the latest news on the flu in the Influenza channel
Newswise

The latest research and expertise on the flue can be found in the Influenza channel on Newswise.

Newswise: National MS Society Awards Dr. Sergio Baranzini the Barancik Prize for Innovation in MS Research
Released: 30-Jan-2024 11:05 AM EST
National MS Society Awards Dr. Sergio Baranzini the Barancik Prize for Innovation in MS Research
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Sergio E. Baranzini, PhD, a geneticist, neuroimmunologist, and data scientist at the University of California, San Francisco, is the winner of this year’s Barancik Prize for Innovation in MS Research.

Released: 30-Jan-2024 9:30 AM EST
Tomato juice’s antimicrobial properties can kill salmonella
American Society for Microbiology (ASM)

Tomato juice can kill Salmonella Typhi and other bacteria that can harm people's digestive and urinary tract health, according to research published this week in Microbiology Spectrum, a journal of the American Society for Microbiology.

   
Newswise:  New technology makes cancer easier for immune system to find and destroy
26-Jan-2024 7:00 AM EST
New technology makes cancer easier for immune system to find and destroy
Hokkaido University

A new technology to increase visibility of cancer cells to the immune system using CRISPR has been developed, and could lead to a new way to treat cancer.

Newswise: Immunologist Lydia Lynch appointed member of Ludwig Princeton
Released: 29-Jan-2024 1:05 PM EST
Immunologist Lydia Lynch appointed member of Ludwig Princeton
Ludwig Cancer Research

It is with great pleasure that we announce the appointment of Lydia Lynch as a full member of the Princeton Branch of the Ludwig Institute for Cancer Research.

Released: 26-Jan-2024 4:05 PM EST
Ursula Storb, immunologist and role model for women scientists, 1936-2023
University of Chicago Medical Center

Storb was a Professor in the Department of Molecular Genetics and Cell Biology for more than 29 years.

Newswise:Video Embedded novel-immunotherapy-selectively-targets-malignant-t-cells
VIDEO
Released: 24-Jan-2024 3:05 PM EST
Novel Immunotherapy Selectively Targets Malignant T Cells
Yale Cancer Center/Smilow Cancer Hospital

One major hurdle in the development of safe and effective immunotherapies has been the risk of depleting healthy T cells during CAR-T treatment that seeks out and kills cancerous T-cells. In a new study published in Nature Communications, Yale Cancer Center researchers have developed a novel CAR-T cell therapy designed to efficiently kill cancerous T cells while leaving most healthy cells intact.

Newswise: How the coronavirus defends itself against our immune system
Released: 24-Jan-2024 1:05 PM EST
How the coronavirus defends itself against our immune system
University of Göttingen

Over 700 million people were infected and almost seven million died, making SARS-CoV-2 the most devastating pandemic of the 21st century.

Newswise: Chemotherapy becomes more efficient when senescent cells are eliminated by immunotherapy
23-Jan-2024 9:30 AM EST
Chemotherapy becomes more efficient when senescent cells are eliminated by immunotherapy
Fundació Institut de Recerca Biomèdica (IRB BARCELONA)

Researchers from IRB Barcelona describe a mechanism by which senescent cells generated by chemotherapy survive inside tumours.

Newswise: RUDN doctors list pros and cons of treating inflammation with macrophages
Released: 22-Jan-2024 4:05 AM EST
RUDN doctors list pros and cons of treating inflammation with macrophages
Scientific Project Lomonosov

RUDN University doctors have studied how anti-inflammatory immune cells can help mitigate an excessive immune response. The authors discovered both positive and negative aspects of the new approach, but overall they proved its promise.



close
2.03598